Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVP-6124 in mild to moderate Alzheimer's disease
NCT02246075Phase 2Withdrawn
- Sponsor
- FORUM Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of encenicline in Alzheimer's disease (AD) (3 arms), sponsored by FORUM Pharmaceuticals. Primary endpoint: Safety/Tolerability of EVP-6124 with concurrent memantine. Planned start Jul 2015; status: withdrawn.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02246075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246075.